Autolus Therapeutics (AUTL) Net Margin (2017 - 2025)
Autolus Therapeutics (AUTL) posted quarterly Net Margin of 372.02% for Q4 2025, up 9482108.0% year-on-year from N/an in Q4 2024, and little changed on a QoQ basis from 373.3% in Q3 2025.
Autolus Therapeutics (AUTL) Net Margin (2017 - 2025) Analysis & Trends
Autolus Therapeutics (AUTL) has reported Net Margin for 9 consecutive years, with 372.02% the latest figure, recorded in Q4 2025.
- Quarterly Net Margin rose 9482108.0% year-over-year to 372.02% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 381.43% (up 179708.0% YoY) and the FY2025 annual result came in at 381.43%, up 179902.0% from the prior year.
- Net Margin steadied at 372.02% in Q4 2025 per AUTL's latest filing, from 373.3% in the prior quarter.
- Over the last five years, Net Margin for AUTL reached as high as 229.02% in Q2 2025 and fell as low as 95193.1% in Q4 2024.
- A 5-year average of 11834.6% and a median of 2003.27% in 2021 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2022 — Net Margin slumped 995996 bps — and 2025, when it jumped 9482108 bps.
- Year by year, Net Margin stood at 14402.97% in 2021, then surged by 95 bps to 737.33% in 2022, then sank by 1432 bps to 11292.86% in 2023, then tumbled by 743 bps to 95193.1% in 2024, then soared by 100 bps to 372.02% in 2025.
- According to Business Quant data, Net Margin over the past three periods registered 372.02%, 373.3%, and 229.02% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 15.02% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 34.53% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 20.17% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 30.33% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Autolus Therapeutics | 404.53 Mn | 103.82 Mn | -1.04 Mn | -372.02% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -372.02% |
| Sep 30, 2025 | -373.30% |
| Jun 30, 2025 | -229.02% |
| Mar 31, 2025 | -781.13% |
| Dec 31, 2024 | -95,193.10% |
| Mar 31, 2024 | -521.68% |
| Sep 30, 2023 | -11,292.86% |
| Mar 31, 2023 | -3,081.35% |
| Dec 31, 2022 | -737.33% |
| Sep 30, 2022 | -1,805.28% |
| Mar 31, 2022 | -22,326.51% |
| Sep 30, 2021 | -14,402.97% |
| Jun 30, 2021 | -2,201.26% |
| Mar 31, 2021 | -12,366.54% |
| Dec 31, 2020 | -10,604.46% |
| Sep 30, 2020 | -8,511.42% |
| Jun 30, 2020 | -10,936.86% |
| Mar 31, 2020 | -8,836.98% |
| Jun 30, 2019 | -2,417.51% |
| Mar 31, 2019 | -1,383.86% |